Delphine Diagnostics well represented at the Princeton Tech Meetup
Princeton, NJ. January 2024: Andy Bala, CEO of Delphine Diagnostics, attended the Princeton Tech Meetup focused on Artificial Intelligence in Healthcare.
Some of the key takeaways are:
- Artificial intelligence-based solutions have recently gained traction in pharma drug discovery, clinical trials, hospital health networks, and product manufacturing. Faster adoption led to better outcomes in business process efficiencies, improved patient outcomes (risk predictions, guidance for surgery planning, improved patient outcomes (such as social determinants, and value-based care for seniors), and of course, financials – Better Operating margin improvements ensuring that the health of the Hospital Health Networks stay robust.
- Responding to a volley of questions from participants, the panelists shared insights on how to solve complex challenges such as bias in data leading to bias in Artificial Intelligence models, and how to improve the accuracy of AI models which could be due to lack of a relevant and real dataset to train models.
- The panel recommended using a governance committee framework with Scientists, Clinicians, Ethics, Compliance, D&I, and the board. The panel also recommended developing and using a responsible Artificial Intelligence model development framework.
We would like to thank Venu Moola and Chris Boroski for the great work done in selecting this much-needed topic and managing the Princeton Tech Meetup.This very engaging panel with such relevant insights would not have been possible without a great panel comprising of Donna Conroy – CEO SciMar ONE, Kash Patel – EVP & CDIO Hackensack Meridian Health, and Rohit Vashisht – CEO WhizAI. Lastly, many thanks Jim Barrood, CEO of Innovation+, who enabled effective interaction among the participants and panelists.
Delphine is proud to be a part of this rapidly growing area of Health Tech!
———————
Delphine Diagnostics Takes Center Stage at NJ Cores Partnering Conference
Princeton, NJ. June 2023:Delphine Diagnostics, a pioneering figure in advanced medical diagnostics, proudly showcased its commitment to scientific collaboration and innovation at the recently concluded New Jersey Research Cores Partnering Conference held this June. The conference brought together leading minds and emerging talents from across the state, with Delphine’s Founder, Andy Bala, and a team comprising Student Interns Isis Gonzalez and Iram Contractor spearheading the company’s representation.
With a focus on nurturing partnerships and igniting transformative ideas, this event was a significant step toward fostering a vibrant scientific community within the region. Delphine Diagnostics seized this occasion to not only share its groundbreaking work but also to establish enduring connections that promise to enrich the scientific landscape.
A notable highlight of the conference was Mr. Bala’s participation as a distinguished panelist. As one of the select Life Sciences startup Eco System Founders from New Jersey, he lent his insights to a discussion centered around the Success Stories of the CSIT Voucher Program. Delphine’s engagement with this program has been pivotal in advancing its cutting-edge research, particularly in enhanced diagnostics, benefitting patients across the global healthcare spectrum.
Delphine Diagnostics expressed its gratitude towards the New Jersey Commission on Science Innovation and Technology Organization (NJ CSIT) for providing this invaluable platform. The exposure garnered from the conference has not only underscored Delphine’s dedication to elevating healthcare standards but has also paved the way for the forthcoming launch of a groundbreaking product – the Sepsis Diagnostics Assay. This revolutionary assay holds the potential to redefine the standard of care for sepsis patients, offering a lifeline that could save countless lives and shield those at risk from this formidable condition.
As Delphine Diagnostics continues to push the boundaries of medical diagnostics, its participation in the NJ Cores Partnering Conference stands as a testament to the company’s unwavering commitment to collaboration, innovation, and ultimately, to the betterment of global healthcare outcomes.
———————
Great news!
Delphine is thrilled to announce that our brilliant Scientist, Dr. Mary Stack, has recently been awarded a grant from the prestigious New Jersey Innovation and Research Fellowship Program. This remarkable achievement brings a wave of excitement to our entire team!
The Innovation and Research Fellowship Program (IRFP) grant serves as a beacon of support for technological research and the thriving innovation ecosystem in New Jersey. With this grant, Delphine aims to revolutionize the field of diagnostic testing with our highly anticipated Sepsis Diagnostic Assay.
Sepsis, a severe and life-threatening condition, demands prompt detection and treatment. However, the current gold standard of blood culture can take up to a painstaking 72 hours to provide results. But fear not! Delphine’s innovative Sepsis Diagnostic Assay seeks to dramatically reduce the time-to-diagnosis to a mere 4 hours, comparable to the swift pace of nucleic acid amplification.
At Delphine Diagnostics, our unwavering focus revolves around identifying and commercializing advancements in diagnostic testing. We wholeheartedly believe that accurate and speedy diagnoses play a vital role in combatting infectious diseases. By improving the accuracy and efficiency of diagnostic tests, we strive to make a significant impact on public health and well-being.
We are bursting with joy and pride as we embark on this groundbreaking journey alongside Dr. Mary Stack. Her dedication and expertise are invaluable assets to our team, and we are confident that her groundbreaking research will pave the way for a brighter future in the field of sepsis diagnosis.
Stay tuned for more updates as we work tirelessly to bring this revolutionary Sepsis Diagnostic Assay to the forefront of medical advancements. Together, let’s shape a world where rapid and accurate diagnostic testing saves lives and brings hope to those in need!
Cheers,
The Delphine Diagnostics Team
*Dr. Stack, the fifth person from the left in the picture
———–
Delphine Diagnostics is at the Roundtable Discussion in Camden
Camden, NJ. April 2023: New Jersey’s Commission on Science, Innovation, and Technology (CSIT) recently organized a valuable event at Rutgers and Rowan University’s Translational Research Facility in Camden, NJ during the last quarter. Delphine Diagnostics was invited to participate in this state-level round table discussion to address pressing issues and challenges facing the life sciences ecosystem.
During the discussion, two key topics were explored:
Q1: Support from the State – What specific type of support would be most impactful for companies like Delphine Diagnostics to grow their business in New Jersey?
Q2: Talent Acquisition – What specific positions do companies like Delphine Diagnostics need to fill for current vacancies and projected future hiring needs to support their growth?
After the discussion, a follow-up communication was shared earlier this month, which included actionable items to address the concerns raised during the round table. Overall, the event proved to be a valuable opportunity for Delphine Diagnostics and other life sciences companies to engage with CSIT and discuss critical issues facing their industry in New Jersey.
Delphine Diagnostics is very grateful to the Executive Leadership and Organizing Committee Members of NJ CSIT, NJ EDA, and NJ DOL for their efforts in organizing this valuable event. It’s clear that this is a positive trend and the engaging and value-add conversation provided an excellent opportunity for industry leaders to come together and discuss critical issues facing the life sciences ecosystem in New Jersey.
The collaborative efforts of these organizations are appreciated and demonstrate a commitment to supporting companies like Delphine Diagnostics as they work to grow and develop within the state. We are grateful for the opportunity to participate in this round table discussion and look forward to continued engagement with NJ CSIT, NJ EDA, and NJ DOL in the future.
————
Panel on Use of Academic and Federal Core Research/Lab Facilities in New Jersey
Princeton, NJ. March 15, 2023: The panel discussion on “Use of Academic and Federal Core Research/Lab Facilities in New Jersey” was a highly informative and beneficial event we recently attended. The panelists were experts in their respective fields. They provided valuable insights into how to access New Jersey’s academic, federal, and nonprofit core labs to accelerate research and development through the Commission on Science Innovation and Technology’s Catalyst and Clean Tech R&D Voucher Grant Program.
The panel was comprised of distinguished individuals such as Vince Smeraglia from Rutgers University, Alex Norman from Princeton University, Irene Wei from CSR Pharma Group, Frances Keel from CSIT, and Nyron Khan from Six Therapeutics. They shared their expertise and answered several questions from the audience, which included entrepreneurs, startup founders, and early-stage firms.
Judith Sheft initiated the panel discussion from CSIT, and Mahako Etta from the same organization moderated the event. The panel was hosted at the Biolabs facility in Princeton, which provided an ideal setting for the discussion.
Overall, the panel discussion provided several key takeaways that will be invaluable for founders of NJ-based startups and early-stage firms. The event was well-organized and highly informative, and we would like to thank the organizers and hosts for their efforts in putting together such a value-added event.
——————-
BioNJ Manufacturing Briefing 2022
Newark, NJ. September 9, 2022: Delphine Diagnostics’ CEO, Andy Bala, attended Manufacturing Briefing 2022 at NJIT and NJ Innovation Institute, both in Newark, NJ. The event was in-person and organized by BioNJ.
BioNJ, McKinsey, a few big pharma firms, and FDA came together to share forward-looking updates relevant to the BioPharma manufacturing space for the next two years.
The highlights of the event were presentations, Q&A sessions, networking, and a walkthrough of McKinsey’s Digital Capability Center- touted as a Digital AI/ML Capability Center – Demonstrated by McKinsey’s team, which was meant for Scientists/Technicians in manufacturing space to learn/hone the needed skills. Andy Bala said, “It was a wonderful event to hear about the manufacturing strategies for the near future and how we can adapt and accelerate along the way. It was also a great networking event, and we found prospective partners to manufacture our Sepsis Diagnostic Kit locally here in New Jersey. “
More info about BioNJ and its upcoming events can be found at the following link: https://bionj.org/
————————-
DELPHINE DIAGNOSTICS INC BECAME AN INAUGURAL MEMBER OF THE SEPSIS INNOVATION COLLABORATIVE (SIC)
Great news from the Delphine team!
Delphine Diagnostics accepted an invitation to join as an inaugural member of the Sepsis Innovation Collaborative (SIC) led by Sepsis Alliance. Delphine’s CEO, Andy Bala, stated that “we look forward to serving by volunteering our time and talents to provide the latest research and marketable products to clinicians and patients. Delphine’s research and development team is committed to providing high-quality data for research and analytical purposes produced by our daily operations.”
More info about SIC: https://lnkd.in/g5Gnipjz
Sepsis Innovation Collaborative (SIC) is a multi-stakeholder public/private collaborative launched by Sepsis Alliance that brings academic, clinical, industry, patient advocacy, reimbursement, research, and other stakeholders together with the common mission to address the challenges and unmet needs related to infection management and sepsis prevention, detection, treatment, and survivor support. SIC members:
– Facilitate public-private communication with U.S. government agencies on opportunities to accelerate innovation
– Develop a common sepsis lexicon
– Connect longitudinal sepsis patient and survivor data
– Improve equity across the infection management/sepsis continuum in underserved communities and vulnerable populations
– Accelerate the time-to-market of novel products and services
– Address the long-term healthcare challenges of sepsis survivors
#sepsisawareness #collaboration #delphinedx #healthcare #opportunities #innovation
————–
BIONJ’S TWELFTH ANNUAL BIOPARTNERING CONFERENCE
New Jersey, May 9, 2022: Biotech Industry Association in New Jersey ‘BioNJ’ had organized a BioPartnering networking event on May 9, 2022, in Liberty Park, New Jersey, across from New York City. Johnson & Johnson and JP Morgan chase were major sponsors of the event. Andy Bala of Delphine Diagnostics was invited as a guest of BioNJ and developed a few contacts to further Delphine’s business interests. Click here for more info!
——————
THE STATE OF THE STATE OF MANUFACTURING
Trenton, NJ, May 5, 2022: Delphine Diagnostics Inc’s CEO, Andy Bala, attended the State of the State of Manufacturing. The event took place in Patriots Theater at the Trenton War Memorial. Andy Bala said, “It was a great initiative to start a dialogue with New Jersey State Legislators and share feedback regarding challenges faced by startup and small to medium-sized manufacturers based out of New Jersey. Absolutely it was a value-add event with two clear goals, driving more diversity in participation and more effective engagement with State Lawmakers in the future at Trenton, NJ.”
More than 400 New Jersey manufacturers gathered in person in the Town Hall style gathering to discuss the challenges and concerns of NJ Manufacturers. More information about NJMEP is below.
Richard Weber of Ethos Biosciences (left), Peter Russo of NJMEP, and Andy Bala- Delphine Diagnostics (right)
ABOUT NJMEP
New Jersey Manufacturing Extension Program, Inc. (NJMEP) is a not-for-profit company that works with New Jersey’s small to mid-sized manufacturers to help them become more efficient, profitable, and globally competitive.
A Meaningful Collaboration Between Rutgers Business School and Delphine Diagnostics Inc
March 17, 2022
In the pictures: Delphine’s CEO, Andy (Andiappan) Bala, is working with the Rutgers Business School students. The students are serving in an excelling program and gaining real work-life experiences. The rewards are countless when investing in young minds, collaboration, expertise, and access.
Delphine at the BAJ Accelerator Program
Delphine Diagnostics Inc. Participated in the BAJ Accelerator Program
New York, January 2022: Delphine Diagnostics Team joined the NYC-based BAJ Accelerator Program as of January 2022 Cohort #7. The program helped build new connections and offered valuable resources to startups. The Delphine Diagnostics Team received compliments, constructive criticism, and training and coaching through the BAJ Accelerator Program. According to Andy Bala, CEO of Delphine, “All in all, it was a great program, and we learned so much about startup business. We are very appreciative of all the support and resources we received.” More information about the program is below. (Source: https://www.bajaccelerator.com)
Picture from the BAJ Accelerator Gallery
ABOUT THE BAJ ACCELERATOR
BAJ Accelerator is a growth stage accelerator and is for startups at the Seed to Series A+ levels. The program includes significant networking opportunities with investors, targeted coaching, customer interviews, collaboration sessions and full-day training sessions from top-level executives from around the globe. Topics span an impressive range including technology, legal, finance, sales, marketing, leadership, storytelling and exponential thinking. The key knowledge goal of BAJ Accelerator is to support founders in enabling their startups to become investable.
BAJ Accelerator was made possible by a collaboration among three organizations: Baltic American Chamber of Commerce, Orion Worldwide Innovations LLC and Jacobs Technion-Cornell Institute at Cornell Tech. Jacobs Technion-Cornell Institute was established jointly by Cornell University and the Technion-Israel Institute of Technology.
HEALTHCARE COMPANIES DISCUSS THEIR INTEREST IN ESTABLISHING THEMSELVES IN PUERTO RICO
We are so thrilled that Delphine Diagnostics’ leadership team participated in the Puerto Rico Biosciences Emerging Companies Network. Our presentation received significant attention, and we made new connections on the island. Special thanks to A4G, The Puerto Rico Economic Development Alliance, for organizing such events, bringing us together, and building platforms.
Thanks to Andy Bala, Ethlyn Haseth – Wolstenholme, Laura M Ferguson, PhD, Sreyashi Samaddar PhD! #delphinedx #delphinediagnostics #healthcare #development #opportunity #growth #team #connections #network #innovation
—
The Puerto Rico Economic Development Alliance hosted a round table with 12 healthcare start-ups where among other topics, the history, attributes, and feasibility of the island were shared to facilitate their entrance into the Puerto Rican market.
The objective was to get to know the Companies that have chosen Puerto Rico or are exploring this market for their development & growth.
“The Alliance wanted to provide the appropriate forum to discuss their vision of development. As well as the areas of opportunity that the island has to attract and retain these industries that see PR as an option to develop and establish their operations”, said Rodrigo Masses.
During the discussion, which was hosted at the Verdanza Hotel in Isla Verde and organized by the Alliance, which is an organization comprised of leaders of the private sector with the objective of providing a platform that serves as a guide to the economic development of the island. It was stated that the goal of the meeting was to meet and guide the Companies that are considering or have chosen Puerto Rico for their growth, their projects and challenges, and what motivates them to select the island.
Among points discussed, the Companies agreed that establishing themselves in PR represents an added value because the island has exceptional talent trained and experienced by the pharmaceutical industry as well as the ideal ecosystem for the development of the industry. Also noted were the challenges to continue developing the industry include energy, changes to the US tax laws, the pandemic, R&D infrastructure, and access to investment capital.
